Drotebanol

DB01547

small molecule experimental illicit

Deskripsi

Struktur Molekul 2D

Berat 333.428
Wujud solid

Peta Jejaring Molekuler
Legenda: ObatTargetGenEnzim(Panah → menunjukkan arah efek / relasi)TransporterCarrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Data absorpsi tidak tersedia.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

664 Data
Buprenorphine Drotebanol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.
Doxylamine Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.
Dronabinol Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.
Droperidol Droperidol may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.
Hydrocodone Drotebanol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.
Hydroxyzine Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.
Magnesium sulfate The therapeutic efficacy of Drotebanol can be increased when used in combination with Magnesium sulfate.
Methotrimeprazine Drotebanol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.
Metyrosine Drotebanol may increase the sedative activities of Metyrosine.
Minocycline Minocycline may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.
Mirtazapine Drotebanol may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
Nabilone Nabilone may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.
Orphenadrine Drotebanol may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
Paraldehyde Drotebanol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
Perampanel Perampanel may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.
Pramipexole Drotebanol may increase the sedative activities of Pramipexole.
Ropinirole Drotebanol may increase the sedative activities of Ropinirole.
Rotigotine Drotebanol may increase the sedative activities of Rotigotine.
Rufinamide The risk or severity of adverse effects can be increased when Rufinamide is combined with Drotebanol.
Sodium oxybate Drotebanol may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.
Suvorexant Drotebanol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.
Tapentadol Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.
Thalidomide Drotebanol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
Zolpidem Drotebanol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Drotebanol.
Ethanol Drotebanol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
Azelastine Drotebanol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
Brimonidine Brimonidine may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.
Fluvoxamine The risk or severity of adverse effects can be increased when Drotebanol is combined with Fluvoxamine.
Citalopram The risk or severity of adverse effects can be increased when Drotebanol is combined with Citalopram.
Duloxetine The risk or severity of adverse effects can be increased when Drotebanol is combined with Duloxetine.
Trazodone The risk or severity of adverse effects can be increased when Drotebanol is combined with Trazodone.
Paroxetine The risk or severity of adverse effects can be increased when Drotebanol is combined with Paroxetine.
Sertraline The risk or severity of adverse effects can be increased when Drotebanol is combined with Sertraline.
Sibutramine The risk or severity of adverse effects can be increased when Drotebanol is combined with Sibutramine.
Nefazodone The risk or severity of adverse effects can be increased when Drotebanol is combined with Nefazodone.
Escitalopram The risk or severity of adverse effects can be increased when Drotebanol is combined with Escitalopram.
Zimelidine The risk or severity of adverse effects can be increased when Drotebanol is combined with Zimelidine.
Dapoxetine The risk or severity of adverse effects can be increased when Drotebanol is combined with Dapoxetine.
Milnacipran The risk or severity of adverse effects can be increased when Drotebanol is combined with Milnacipran.
Desvenlafaxine The risk or severity of adverse effects can be increased when Drotebanol is combined with Desvenlafaxine.
Seproxetine The risk or severity of adverse effects can be increased when Drotebanol is combined with Seproxetine.
Indalpine The risk or severity of adverse effects can be increased when Drotebanol is combined with Indalpine.
Ritanserin The risk or severity of adverse effects can be increased when Drotebanol is combined with Ritanserin.
Alaproclate The risk or severity of adverse effects can be increased when Drotebanol is combined with Alaproclate.
Amitriptyline The risk or severity of CNS depression can be increased when Amitriptyline is combined with Drotebanol.
Cyproheptadine The risk or severity of CNS depression can be increased when Cyproheptadine is combined with Drotebanol.
Imipramine The risk or severity of CNS depression can be increased when Imipramine is combined with Drotebanol.
Nortriptyline The risk or severity of CNS depression can be increased when Nortriptyline is combined with Drotebanol.
Amoxapine The risk or severity of CNS depression can be increased when Amoxapine is combined with Drotebanol.
Propiomazine The risk or severity of CNS depression can be increased when Propiomazine is combined with Drotebanol.
Maprotiline The risk or severity of CNS depression can be increased when Maprotiline is combined with Drotebanol.
Doxepin The risk or severity of CNS depression can be increased when Doxepin is combined with Drotebanol.
Desipramine The risk or severity of CNS depression can be increased when Desipramine is combined with Drotebanol.
Pizotifen The risk or severity of CNS depression can be increased when Drotebanol is combined with Pizotifen.
Dosulepin The risk or severity of CNS depression can be increased when Drotebanol is combined with Dosulepin.
Zopiclone The risk or severity of adverse effects can be increased when Drotebanol is combined with Zopiclone.
Botulinum toxin type B The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with Drotebanol.
Botulinum toxin type A The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with Drotebanol.
Tryptophan The risk or severity of CNS depression can be increased when Tryptophan is combined with Drotebanol.
Baclofen Baclofen may increase the central nervous system depressant (CNS depressant) activities of Drotebanol.
Lorazepam The risk or severity of CNS depression can be increased when Lorazepam is combined with Drotebanol.
Ethchlorvynol The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with Drotebanol.
Succinylcholine The risk or severity of CNS depression can be increased when Succinylcholine is combined with Drotebanol.
Reserpine The risk or severity of CNS depression can be increased when Reserpine is combined with Drotebanol.
Eletriptan The risk or severity of CNS depression can be increased when Eletriptan is combined with Drotebanol.
Enflurane The risk or severity of CNS depression can be increased when Enflurane is combined with Drotebanol.
Temazepam The risk or severity of CNS depression can be increased when Temazepam is combined with Drotebanol.
Reboxetine The risk or severity of CNS depression can be increased when Reboxetine is combined with Drotebanol.
Butabarbital The risk or severity of CNS depression can be increased when Butabarbital is combined with Drotebanol.
Butalbital The risk or severity of CNS depression can be increased when Butalbital is combined with Drotebanol.
Methysergide The risk or severity of CNS depression can be increased when Methysergide is combined with Drotebanol.
Cabergoline The risk or severity of CNS depression can be increased when Cabergoline is combined with Drotebanol.
Phenytoin The risk or severity of CNS depression can be increased when Phenytoin is combined with Drotebanol.
Topiramate The risk or severity of CNS depression can be increased when Topiramate is combined with Drotebanol.
Clemastine The risk or severity of CNS depression can be increased when Clemastine is combined with Drotebanol.
Venlafaxine The risk or severity of CNS depression can be increased when Venlafaxine is combined with Drotebanol.
Etomidate The risk or severity of CNS depression can be increased when Etomidate is combined with Drotebanol.
Morphine The risk or severity of CNS depression can be increased when Morphine is combined with Drotebanol.
Talbutal The risk or severity of CNS depression can be increased when Talbutal is combined with Drotebanol.
Pentobarbital The risk or severity of CNS depression can be increased when Pentobarbital is combined with Drotebanol.
Valproic acid The risk or severity of CNS depression can be increased when Valproic acid is combined with Drotebanol.
Zolmitriptan The risk or severity of CNS depression can be increased when Zolmitriptan is combined with Drotebanol.
Codeine The risk or severity of CNS depression can be increased when Codeine is combined with Drotebanol.
Dihydroergotamine The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with Drotebanol.
Tolcapone The risk or severity of CNS depression can be increased when Tolcapone is combined with Drotebanol.
Hydromorphone The risk or severity of CNS depression can be increased when Hydromorphone is combined with Drotebanol.
Olanzapine The risk or severity of CNS depression can be increased when Olanzapine is combined with Drotebanol.
Cetirizine The risk or severity of CNS depression can be increased when Cetirizine is combined with Drotebanol.
Protriptyline The risk or severity of CNS depression can be increased when Protriptyline is combined with Drotebanol.
Trimethadione The risk or severity of CNS depression can be increased when Trimethadione is combined with Drotebanol.
Clobazam The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with Drotebanol.
Chlorzoxazone The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with Drotebanol.
Clozapine The risk or severity of CNS depression can be increased when Clozapine is combined with Drotebanol.
Meprobamate The risk or severity of CNS depression can be increased when Meprobamate is combined with Drotebanol.
Thiethylperazine The risk or severity of CNS depression can be increased when Thiethylperazine is combined with Drotebanol.
Palonosetron The risk or severity of CNS depression can be increased when Palonosetron is combined with Drotebanol.
Sulpiride The risk or severity of CNS depression can be increased when Sulpiride is combined with Drotebanol.
Alprazolam The risk or severity of CNS depression can be increased when Alprazolam is combined with Drotebanol.
Dexbrompheniramine The risk or severity of CNS depression can be increased when Dexbrompheniramine is combined with Drotebanol.

Referensi & Sumber

Belum ada data referensi/link/attachment untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field referensi.

Contoh Produk & Brand

Produk: 0 • International brands: 0
Belum ada data produk/brand untuk obat ini pada database. Jalankan import DrugBank untuk mengisi field produk/brand.

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul